Who Paid My Doc
Richard Smith
Ocoee, FL Medical Doctor
NPI 1033213749 CMS profile 92507
1555 Boren Dr, Ocoee, FL 34761
General payments
$7,703
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Richard Smith of Ocoee, FL is reported in the CMS Open Payments database as having received $7,703 across 57 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $16 | 1 | |
| 2022 | General | $76 | 5 | |
| 2021 | General | $294 | 12 | |
| 2020 | General | $174 | 11 | |
| 2019 | General | $7,143 | 28 |
Beside peers
- Richard Smith
- Florida median
- Middle half of Florida
- National median
In program year 2025, general payments to Richard Smith were reported at $0. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.
Show as a table
| Year | Richard Smith | Florida median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $7,143 | $197 | $63–$719 | $163 |
| 2020 | $174 | $126 | $38–$436 | $114 |
| 2021 | $294 | $151 | $45–$537 | $132 |
| 2022 | $76 | $175 | $53–$607 | $149 |
| 2023 | $16 | $183 | $57–$637 | $160 |
| 2024 | $0 | $185 | $56–$647 | $164 |
| 2025 | $0 | $195 | $59–$690 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
112
Drug cost
$23,098
Branded share of claims
51.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtampza Er Oxycodone Myristate | Brand | 24 | $22,081 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 23 | $374 | |
| Celecoxib | Generic | 24 | $341 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 11 | $193 | |
| Tramadol Hcl | Generic | 19 | $63 | |
| Ibuprofen | Generic | 11 | $47 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$5,975
Medicare patients
29
Services billed
131
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Ischemic heart disease | 41% | |
| Chronic kidney disease | 41% | |
| Diabetes | 38% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 12 | 51 | $276 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
57 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.